Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma

PHASE3TerminatedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
DRUG

Lymphoseek

Single injection of 50 micrograms Lymphoseek radiolabeled with either 0.5 mCi (for same day surgery) or 2.0 mCi (for next day surgery) of Tc 99m

Trial Locations (13)

19107

Thomas Jefferson University, Philadelphia

27710

Duke University Medical Center, Durham

33136

University of Miami, Sylvester Comprehensive Cancer Center, Miami

35294

University of Alabama, Birmingham, Birminham

39216

University of Mississippi, Jackson

43210

The Ohio State University Comprehensive Cancer Center, Columbus

48109

University of Michigan Medical Center, Ann Arbor

65203

University of Missouri-Ellis Fischel Cancer Center, Columbia

66160

University of Kansas Medical Center, Kansas City

68198

University of Nebraska, Omaha

77030

MD Anderson, Houston

92093

Moores UCSD Cancer Center, La Jolla

92161

San Diego VA Hospital, San Diego

Sponsors
All Listed Sponsors
lead

Navidea Biopharmaceuticals

INDUSTRY

NCT00911326 - Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter